Intervention effect of targeted workplace closures may be approximated by single-layered networks in an individual-based model of COVID-19 control.

Publication date: Jul 26, 2024

Individual-based models of infectious disease dynamics commonly use network structures to represent human interactions. Network structures can vary in complexity, from single-layered with homogeneous mixing to multi-layered with clustering and layer-specific contact weights. Here we assessed policy-relevant consequences of network choice by simulating different network structures within an established individual-based model of SARS-CoV-2 dynamics. We determined the clustering coefficient of each network structure and compared this to several epidemiological outcomes, such as cumulative and peak infections. High-clustered networks estimate fewer cumulative infections and peak infections than less-clustered networks when transmission probabilities are equal. However, by altering transmission probabilities, we find that high-clustered networks can essentially recover the dynamics of low-clustered networks. We further assessed the effect of workplace closures as a layer-targeted intervention on epidemiological outcomes and found in this scenario a single-layered network provides a sufficient approximation of intervention effect relative to a multi-layered network when layer-specific contact weightings are equal. Overall, network structure choice within models should consider the knowledge of contact weights in different environments and pathogen mode of transmission to avoid over- or under-estimating disease burden and impact of interventions.

Open Access PDF

Concepts Keywords
Covid Based
Epidemiological Closures
Infectious Clustered
Weights Contact
Workplace Dynamics
Individual
Infections
Intervention
Layer
Layered
Network
Networks
Targeted
Transmission
Workplace

Semantics

Type Source Name
disease IDO intervention
disease MESH COVID-19
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH infections
drug DRUGBANK Aspartame
disease IDO pathogen
drug DRUGBANK Coenzyme M
disease IDO pathogen host
disease VO population
disease VO Gap
disease VO injection
disease VO vaccination
disease IDO infection
disease MESH reinfection
disease VO time
disease IDO process
disease IDO facility
disease VO effective
disease MESH uncertainty
disease MESH influenza
disease VO Respiratory syncytial virus
drug DRUGBANK Nevirapine
disease VO effectiveness
drug DRUGBANK Etoperidone
disease IDO infectivity
drug DRUGBANK Serine
disease IDO contact tracing
disease IDO susceptibility
disease VO USA
disease VO syringe
disease IDO immunodeficiency
disease VO vaccine
disease VO frequency

Original Article

(Visited 2 times, 1 visits today)